Complete report $12,500. Individual company assessments $1,900. This unique report was provides Life Science industry executives with strategically significant competitor information, analysis and insight crucial to the development and implementation of effective business, marketing and R&D programs. The companies analyzed in the report include: BASF, Cambrex, Clariant, DowPharma, DSM, Evonik, Lanxess, Lonza, Novasep, and Rhodia. Objectives • To establish a comprehensive, factual and cost-effective information base on performance, capabilities, goals and strategies of the world’s leading life science intermediates companies. • To help current suppliers realistically assess their financial, technological and marketing capabilities vis-a-vis leading competitors. • To assist potential market entrants in evaluating prospective acquisitions and joint venture candidates. • To complement organizations’ internal competitor information gathering efforts with strategic analysis, data interpretation and insight. Rationale A strategic assessment of the competitive environment is widely recognized as one of the highest priority management responsibilities, the task crucial to business survival, growth and profitability. Timely and factual competitive intelligence is vital to the success of all business functions, particularly Planning, Marketing, R&D, and Manufacturing.
In a highly dynamic and fragmented life science intermediates market, besieged by intense competition and rapid pace of technological innovations, the ability to anticipate new competitive product introductions and marketing strategies is particularly important... and can spell the difference between success and failure. Methodology The Top 10 report is based on a combination of primary and secondary information sources, including Venture Planning Group’s proprietary database, developed during the firm’s continuous monitoring of the industry, as well as over 100 syndicated studies and numerous proprietary single-client assignments. VPG database contains information on major life science intermediates companies, technologies, products and executives worldwide. Moreover, a comprehensive review of the Top 10 companies’ product and financial literature, business and technical periodicals, and pertinent industry analyst reports was conducted. Contains 600 pages and 84 tables
|